Last reviewed · How we verify

2011-2012 FluMist®

Stanford University · FDA-approved active Biologic Quality 2/100

FluMist®, developed by Stanford University, is a marketed influenza vaccine with a key composition patent expiring in 2028. The primary strength of FluMist® lies in its unique mechanism of delivery, offering a needle-free alternative to traditional flu vaccines. The primary risk is the competitive landscape, with multiple established flu vaccines in the market.

At a glance

Generic name2011-2012 FluMist®
Also known asLive, attenuated influenza vaccine (LAIV), FDA-licensed seasonal influenza vaccine
SponsorStanford University
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: